MeritValue

NP Life Sciences Health Industry Group Inc.

ACATdata completeness 75%5 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'totalDebt'

The thesis, from the filings

NP Life Sciences Health Industry Group Inc. earns about -92% on equity, with a roughly flat share count. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2019FY 2020FY 2021FY 2022FY 2023
Revenue$43,0001$15,0002$34,9923$102,0024$164,6214
Net income−$108,8275−$131,0656−$65,6777−$18,8568−$2,9358
Operating cash flow−$4,2669−$124,32210−$90,62511$93,87312−$73,60712
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$242,93313$118,61114$27,98615$121,85916$70,61416
Diluted shares43.0M43.0M43.0M43.0M43.0M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$0
your share of equity
Profit it earned you last year
−$0
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $0 of net worth that earned you −$0 last year.

iii. Is this a good business?
Moat signal · return on equity
-92% avg · 5y
FY19 -46%FY20 -126%FY21 -172%FY22 -98%FY23 -18%

It earned an average -92% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−0% shares · 5y

Share count is roughly flat over 5 years — little dilution, little buyback.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2019-12-31 · accession 0001493152-21-008899 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K · period ending 2020-12-31 · accession 0001493152-22-010074 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K · period ending 2021-12-31 · accession 0001493152-23-012632 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K · period ending 2022-12-31 · accession 0001493152-24-014774 (RevenueFromContractWithCustomerExcludingAssessedTax)
  5. 10-K · period ending 2019-12-31 · accession 0001493152-21-008899 (NetIncomeLoss)
  6. 10-K · period ending 2020-12-31 · accession 0001493152-22-010074 (NetIncomeLoss)
  7. 10-K · period ending 2021-12-31 · accession 0001493152-23-012632 (NetIncomeLoss)
  8. 10-K · period ending 2022-12-31 · accession 0001493152-24-014774 (NetIncomeLoss)
  9. 10-K · period ending 2019-12-31 · accession 0001493152-21-008899 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2020-12-31 · accession 0001493152-22-010074 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2021-12-31 · accession 0001493152-23-012632 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2022-12-31 · accession 0001493152-24-014774 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2019-12-31 · accession 0001493152-21-008899 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2020-12-31 · accession 0001493152-22-010074 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2021-12-31 · accession 0001493152-23-012632 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2022-12-31 · accession 0001493152-24-014774 (CashAndCashEquivalentsAtCarryingValue)